Phitech raises $2.4M to advance multi-omics AI platform for rare diseases and cancer

TechBio startup PhiTech has raised $2.4 million in its third funding round to further develop its multi-omics AI platform for rare diseases and cancer. Founded by Dr. Saliha Durmuş, Prof. Dr. Tunahan Çakır, and Prof. Dr. Erdoğan Sevilgen, PhiTech plans to use the new funding to accelerate market expansion and position itself as a global player in precision medicine.

The round was led by Entertech VC, established through a collaboration between Entertech Istanbul Technopark and Yapı Kredi Portfolio Management. Participating investors include Eksim Ventures, Founder One, ITK Ventures, TechnoBee, and a group of angel investors, including Muharrem Usta, Kamil Buğra Rodoper, Banu Başaran, Mert Erdoğmuş, Ahmet Kemal Atasoy, Adem Akkaya, Zeynep Seval, and Selami Düz. Existing investors Arya VC, Istcapital, Gelecek Etki GSYF, Candan Karabağlı, and Osman Alp Arlı also joined the round.

At the core of PhiTech’s offering is its clinical decision support platform, G&M (Genomics & More), which integrates DNA (genomics) and RNA (transcriptomics) sequencing data to generate actionable insights for hospitals, genetic diagnostic laboratories, and pharmaceutical companies, supporting diagnosis, treatment decisions, and drug development in genetic diseases. By combining genomics and transcriptomics data, PhiTech aims to improve diagnostic outcomes in cases where DNA-only testing falls short. The company positions itself at the forefront of the shift from DNA-based diagnostics to multi-omics approaches in clinical practice. PhiTech is headquartered in Türkiye, where its R&D activities are concentrated, and also operates in the US and the Netherlands. The company reports ongoing progress in international patent filings related to its AI technologies.

Globally, rare diseases affect an estimated 400 million people, including around 5 million in Türkiye. Patients often wait more than six years for an accurate diagnosis, and DNA-only diagnostic approaches typically achieve rates below 40%. With the G&M platform, PhiTech has started to increase diagnostic yield and make this process faster and more accessible. In Türkiye, G&M has enabled medical geneticists to diagnose dozens of previously unresolved cases over the past year, including patients who had gone years without a diagnosis despite DNA-based testing. With the new funding, the company plans to further advance its multi-omics AI capabilities in rare diseases while completing R&D efforts for its cancer-focused solutions.